查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602234

白斑症治疗药物市场：依治疗方法、疾病类型、药物类型、最终用户、通路 - 全球预测 2025-2030

Vitiligo Therapeutics Market by Treatment (Light Therapy, Surgical Procedures, Topical Treatment), Disease Type (Nonsegmental Vitiligo, Segmental Vitiligo), Drug Type, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年白斑症治疗药物市值为14.5亿美元，预计2024年将达到15.6亿美元，复合年增长率为8.43%，到2030年预计将达到25.5亿美元。

白斑症治疗包括旨在控制和逆转白斑症（一种以色素沉着为特征的皮肤病）的各种治疗和干预措施。此市场范围涵盖各种药物疗法，如局部固醇、Calcineurin抑制剂、照光治疗、新型生物製药和小分子化合物。这些治疗的需求源自于医疗和社会心理需求，因为白斑症会导致严重的心理困扰和社会耻辱。适用范围包括医院、皮肤科诊所和家庭治疗，最终使用者包括儿童和成人患者。市场驱动因素包括寻常型白斑症盛行率的增加、意识的提高以及新疗法研发的快速增加。 JAK 抑制剂和基因治疗等创新技术的出现为白斑症治疗的个人化医疗提供了新领域的潜在机会。透过利用策略联盟和投资于专注于新治疗方法的长期疗效和安全性的高级研究，鼓励利用这些机会进行研究。然而，仍存在可能阻碍市场成长的限制，例如治疗成本高、对白斑症病理学的不完全了解以及监管障碍。挑战包括患者反应的变化和病情的慢性性质，需要继续研究适应性治疗通讯协定。创新领域包括开发非侵入性诊断工具、透过数位健康平台提高患者依从性以及探索微生物组在皮肤健康中的作用。白斑症治疗市场的特点是技术快速进步并向以患者为中心的护理模式转变，呈现出巨大的业务成长潜力。该领域的相关人员应专注于加强学术界、产业和患者倡导团体之间的合作，以促进全面、渐进的治疗发展方法。

主要市场统计
基准年[2023] 14.5亿美元
预测年份 [2024] 15.6亿美元
预测年份 [2030] 25.5亿美元
复合年增长率（%） 8.43%

市场动态：揭示快速发展的白斑症治疗市场的关键市场洞察

白斑症药物市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球白斑症病例不断增加
    • 对有效治疗方法的认识不断增强
  • 市场限制因素
    • 白斑症治疗和产品召回的潜在风险
  • 市场机会
    • 增加有效白斑药物开发的临床试验及研发活动
    • 白斑症治疗药物的有利报销方案
  • 市场挑战
    • 发展中地区的治疗方法有限，而且白斑药物有副作用的风险。

波特五力：驾驭白斑药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解白斑症治疗药物市场的外在影响

外部宏观环境因素在塑造白斑症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解白斑症治疗药物市场的竞争状况

白斑症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，以应对日益激烈的竞争。

FPNV定位矩阵白斑症治疗药物市场供应商绩效评估

FPNV定位矩阵是评估白斑症治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球白斑症病例不断增加
      • 提高人们对有效治疗方法的认识
    • 抑制因素
      • 白斑症治疗和产品召回的潜在风险
    • 机会
      • 增加临床试验和研发活动，有效开发白斑治疗药物
      • 白斑症治疗药物的有利报销方案
    • 任务
      • 发展中地区的治疗方法有限，且有与白斑药物相关的副作用风险。
  • 市场区隔分析
    • 治疗：光疗的重大技术进步
    • 疾病类型：节段性白斑症盛行率上升
    • 药物类型：JAK抑制剂治疗白斑效果良好
    • 最终使用者：由于成本效益，对皮肤科诊所的兴趣正在增加
    • 分销通路：网路药局通路呈现成长趋势
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 依治疗分類的白斑症治疗药物市场

  • 光疗
  • 外科手术
    • 细胞移植
    • 植皮
  • 局部治疗

第七章白斑症治疗药物市场：依疾病类型

  • 非节段性白斑
  • 节段性白斑

第八章白斑症治疗药物市场依药物类型划分

  • Calcineurin抑制剂
  • Calcipotriene
  • 皮质类固醇
  • JAK抑制剂

第九章白斑症治疗药物市场：依最终用户分类

  • 医院
  • 皮肤科诊所

第10章白斑症治疗药物市场：依通路分类

  • 医院药房
  • 网路药房
  • 零售药房

第十一章 北美、南美白斑症治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区白斑症治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲白斑症治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Clinuvel 开始白斑症国际 III 期研究
    • 艾伯维 (AbbVie) 宣布Upadacitinib(Rinvoc) 在白斑症 2 期临床试验中达到主要终点，并将计画推进至 3 期
    • Glenmark Pharmaceuticals 0.03%Tacrolimus软膏获得 sANDA核准
    • AVITA Medical 宣布 FDA核准RECELL 用于白斑症患者的皮肤色素沉着治疗
    • Insight 宣布欧盟委员会核准Opzella (Ruxolitinib) 霜用于治疗成人和青少年面部非节段性白斑
    • 麻省理工学院陈学院 (MIT Chan College) 向 Ardena Therapeutics 授予 siRNA 化学许可，用于开发皮肤病治疗方法
    • 加拿大卫生署核准Edesa Biotech 的白斑症治疗试验
    • Ahamne Biosciences 完成白斑症治疗第一期临床试验
    • Insight 宣布与 Medixie 支持的 Viralis Therapeutics 就抗 IL-15RB 单株抗体 Auremolimab (VM6) 达成收购协议
    • Almirall 和 Inselm Transfer 签署白斑症调查合约

公司名单

  • Clinuvel Pharmaceuticals Ltd.
  • Merck KGaA
  • ISSAR pharmaceuticals Pvt. Ltd.
  • Vyne Therapeutics, Inc.
  • Glenmark Pharmaceuticals Limited
  • Organic Care Australia Pty Ltd.
  • AbbVie Inc.
  • TeVido BioDevices
  • SESDERMA, SL
  • Biocon Limited
  • Dermavant Sciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Array Skin Therapy
  • Koninklijke Philips NV
  • Astellas Pharma, Inc.
  • Kernel Medical Equipment Co.,LTD
  • Mylan NV by Viatris Inc.
  • Stem Cell Care India
  • SOMA Skin & Laser, LLC
  • Accord Healthcare, Inc.
  • Incyte Corporation
  • Strides Pharma Science Limited
  • Pierre Fabre SA
  • Panacea Biotec Limited
  • The Daavlin Company
  • Novartis AG
  • Arcutis Biotherapeutics, Inc.
  • Amgen Inc.
  • JN Biosciences LLC
  • Philadelphia Pharmaceuticals
  • Clarify Health Solutions, Inc.
  • Edesa Biotech, Inc.
  • AVITA Medical, Inc.
  • UNIZA Group
  • Temprian Therapeutics Inc.
  • Ahammune Biosciences Pvt. Ltd.
  • Puneet Laboratories Pvt. Ltd.
  • Bausch Health Companies Inc.
  • Pfizer Inc.
  • Nova Dermatology
Product Code: MRR-742BD51851D2

The Vitiligo Therapeutics Market was valued at USD 1.45 billion in 2023, expected to reach USD 1.56 billion in 2024, and is projected to grow at a CAGR of 8.43%, to USD 2.55 billion by 2030.

Vitiligo therapeutics encompass a range of medical treatments and interventions aimed at managing and potentially reversing the effects of vitiligo, a skin condition characterized by the loss of pigmentation. The scope of this market extends across various pharmacological therapies, such as topical corticosteroids, calcineurin inhibitors, phototherapy, and emerging biologics and small molecules. The necessity for these treatments stems from both medical and psychosocial needs, as vitiligo can lead to significant emotional distress and social stigmatization. The application spectrum covers hospital settings, dermatology clinics, and home-based treatments, with end-users including both pediatric and adult patients. Key market drivers include increasing prevalence of vitiligo, heightened awareness, and burgeoning research and development in novel therapeutics. Innovations such as JAK inhibitors and gene therapy emerge as potential opportunities, providing new frontiers for personalized medicine in vitiligo care. Recommendations for leveraging these opportunities involve tapping into strategic alliances and investing in advanced research focused on long-term efficacy and safety profiles of emerging therapies. Nevertheless, limitations persist, including high treatment costs, incomplete understanding of vitiligo's pathogenesis, and regulatory hurdles, which may impede market growth. Challenging factors also involve variability in patient response and the chronic nature of the condition, calling for ongoing research in adaptive treatment protocols. Areas ripe for innovation include developing non-invasive diagnostic tools, enhancing patient adherence through digital health platforms, and exploring the microbiome's role in skin health. The vitiligo therapeutics market is characterized by fast-evolving technological advances and a shift toward patient-centered care models, underscoring the potential for significant business growth. Stakeholders in this sector should focus on increasing collaboration between academia, industry, and patient advocacy groups to foster an inclusive and progressive approach to treatment development.

KEY MARKET STATISTICS
Base Year [2023] USD 1.45 billion
Estimated Year [2024] USD 1.56 billion
Forecast Year [2030] USD 2.55 billion
CAGR (%) 8.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vitiligo Therapeutics Market

The Vitiligo Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising cases of vitiligo across the globe
    • Growing awareness regarding the availability of effective treatments
  • Market Restraints
    • Potential risk of vitiligo drug and product recall
  • Market Opportunities
    • Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
    • Favorable reimbursement scenario for vitiligo therapeutics
  • Market Challenges
    • Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Vitiligo Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vitiligo Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vitiligo Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vitiligo Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vitiligo Therapeutics Market

A detailed market share analysis in the Vitiligo Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vitiligo Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vitiligo Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Vitiligo Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Clinuvel Pharmaceuticals Ltd., Merck KGaA, ISSAR pharmaceuticals Pvt. Ltd., Vyne Therapeutics, Inc., Glenmark Pharmaceuticals Limited, Organic Care Australia Pty Ltd., AbbVie Inc., TeVido BioDevices, SESDERMA, S.L, Biocon Limited, Dermavant Sciences, Inc., Dr. Reddy's Laboratories Ltd., Array Skin Therapy, Koninklijke Philips N.V., Astellas Pharma, Inc., Kernel Medical Equipment Co.,LTD, Mylan N.V. by Viatris Inc., Stem Cell Care India, SOMA Skin & Laser, LLC, Accord Healthcare, Inc., Incyte Corporation, Strides Pharma Science Limited, Pierre Fabre S.A, Panacea Biotec Limited, The Daavlin Company, Novartis AG, Arcutis Biotherapeutics, Inc., Amgen Inc., JN Biosciences LLC, Philadelphia Pharmaceuticals, Clarify Health Solutions, Inc., Edesa Biotech, Inc., AVITA Medical, Inc., UNIZA Group, Temprian Therapeutics Inc., Ahammune Biosciences Pvt. Ltd., Puneet Laboratories Pvt. Ltd., Bausch Health Companies Inc., Pfizer Inc., and Nova Dermatology.

Market Segmentation & Coverage

This research report categorizes the Vitiligo Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Light Therapy, Surgical Procedures, and Topical Treatment. The Surgical Procedures is further studied across Cell Transplant and Skin Graft.
  • Based on Disease Type, market is studied across Nonsegmental Vitiligo and Segmental Vitiligo.
  • Based on Drug Type, market is studied across Calcineurin Inhibitors, Calcipotriene, Corticosteroids, and JAK inhibitor.
  • Based on End User, market is studied across Hospitals and Skin Clinics.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising cases of vitiligo across the globe
      • 5.1.1.2. Growing awareness regarding the availability of effective treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of vitiligo drug and product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing number of clinical trials and R&D activities for the development of efficient vitiligo therapeutics
      • 5.1.3.2. Favorable reimbursement scenario for vitiligo therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Limited reach of therapies in developing regions coupled with the risk of adverse effects associated with vitiligo therapeutics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Significant technological advancements in light therapies
    • 5.2.2. Disease Type: Rising prevalence of segmental vitiligo disorder
    • 5.2.3. Drug Type: Promising therapeutic action of JAK inhibitors for vitiligo management
    • 5.2.4. End User: Growing preference for skin clinics due to cost effectiveness
    • 5.2.5. Distribution Channel: Rising inclination towards online pharmacy channels
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vitiligo Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Light Therapy
  • 6.3. Surgical Procedures
    • 6.3.1. Cell Transplant
    • 6.3.2. Skin Graft
  • 6.4. Topical Treatment

7. Vitiligo Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Nonsegmental Vitiligo
  • 7.3. Segmental Vitiligo

8. Vitiligo Therapeutics Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Calcineurin Inhibitors
  • 8.3. Calcipotriene
  • 8.4. Corticosteroids
  • 8.5. JAK inhibitor

9. Vitiligo Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Skin Clinics

10. Vitiligo Therapeutics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Vitiligo Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vitiligo Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vitiligo Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinuvel Starts Global Phase III Vitiligo Study
    • 14.3.2. AbbVie Announces Upadacitinib (RINVOQ) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
    • 14.3.3. Glenmark Pharmaceuticals Receives sANDA Approval for Tacrolimus Ointment, 0.03%
    • 14.3.4. AVITA Medical Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients
    • 14.3.5. Incyte Announces European Commission Approval Of Opzelura (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
    • 14.3.6. UMass Chan Licensed siRNA chemistry to Aldena Therapeutics To Develop Therapies For Dermatological Diseases
    • 14.3.7. Health Canada Grants Approval for Edesa Biotech's Vitiligo Therapy Trial
    • 14.3.8. Ahammune Biosciences Completes Phase I Clinical Trial For Vitiligo Drug
    • 14.3.9. Incyte Announces Agreement To Acquire Medicxi-Backed Villaris Therapeutics And Auremolimab (VM6), An Anti-IL-15RB Monoclonal Antibody
    • 14.3.10. Almirall, Inserm Transfert Enter Agreement for Vitiligo Research

Companies Mentioned

  • 1. Clinuvel Pharmaceuticals Ltd.
  • 2. Merck KGaA
  • 3. ISSAR pharmaceuticals Pvt. Ltd.
  • 4. Vyne Therapeutics, Inc.
  • 5. Glenmark Pharmaceuticals Limited
  • 6. Organic Care Australia Pty Ltd.
  • 7. AbbVie Inc.
  • 8. TeVido BioDevices
  • 9. SESDERMA, S.L
  • 10. Biocon Limited
  • 11. Dermavant Sciences, Inc.
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Array Skin Therapy
  • 14. Koninklijke Philips N.V.
  • 15. Astellas Pharma, Inc.
  • 16. Kernel Medical Equipment Co.,LTD
  • 17. Mylan N.V. by Viatris Inc.
  • 18. Stem Cell Care India
  • 19. SOMA Skin & Laser, LLC
  • 20. Accord Healthcare, Inc.
  • 21. Incyte Corporation
  • 22. Strides Pharma Science Limited
  • 23. Pierre Fabre S.A
  • 24. Panacea Biotec Limited
  • 25. The Daavlin Company
  • 26. Novartis AG
  • 27. Arcutis Biotherapeutics, Inc.
  • 28. Amgen Inc.
  • 29. JN Biosciences LLC
  • 30. Philadelphia Pharmaceuticals
  • 31. Clarify Health Solutions, Inc.
  • 32. Edesa Biotech, Inc.
  • 33. AVITA Medical, Inc.
  • 34. UNIZA Group
  • 35. Temprian Therapeutics Inc.
  • 36. Ahammune Biosciences Pvt. Ltd.
  • 37. Puneet Laboratories Pvt. Ltd.
  • 38. Bausch Health Companies Inc.
  • 39. Pfizer Inc.
  • 40. Nova Dermatology

LIST OF FIGURES

  • FIGURE 1. VITILIGO THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. VITILIGO THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VITILIGO THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VITILIGO THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY LIGHT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN GRAFT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY TOPICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY NONSEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SEGMENTAL VITILIGO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CALCIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY JAK INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY SKIN CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VITILIGO THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES VITILIGO THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM VITILIGO THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. VITILIGO THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. VITILIGO THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023